Next Article in Journal
Zinc Intake and Status and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Association of Folate and Vitamins Involved in the 1-Carbon Cycle with Polymorphisms in the Methylenetetrahydrofolate Reductase Gene (MTHFR) and Global DNA Methylation in Patients with Colorectal Cancer
Previous Article in Journal
Consumption of Dark Green Leafy Vegetables Predicts Vitamin A and Iron Intake and Status among Female Small-Scale Farmers in Tanzania
Previous Article in Special Issue
Adherence to Cancer Prevention Guidelines among Older White and Black Adults in the Health ABC Study

Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways

Medlab Clinical, Sydney, NSW 2015, Australia
Centre for Clinical Research, The University of Queensland, Royal Brisbane & Women’s Hospital Campus, Herston, Brisbane, QLD 4029, Australia
Sydney Medical School, Faculty Medicine and Health, The University of Sydney, Sydney 2006, Australia
Author to whom correspondence should be addressed.
Nutrients 2019, 11(5), 1026;
Received: 26 March 2019 / Revised: 29 April 2019 / Accepted: 5 May 2019 / Published: 7 May 2019
(This article belongs to the Special Issue Nutrition and Cancer: From Prevention to Survivorship)
The intestinal microbiota is well known to have multiple benefits on human health, including cancer prevention and treatment. The effects are partially mediated by microbiota-produced short chain fatty acids (SCFAs) such as butyrate, propionate and acetate. The anti-cancer effect of butyrate has been demonstrated in cancer cell cultures and animal models of cancer. Butyrate, as a signaling molecule, has effects on multiple signaling pathways. The most studied effect is its inhibition on histone deacetylase (HDAC), which leads to alterations of several important oncogenic signaling pathways such as JAK2/STAT3, VEGF. Butyrate can interfere with both mitochondrial apoptotic and extrinsic apoptotic pathways. In addition, butyrate also reduces gut inflammation by promoting T-regulatory cell differentiation with decreased activities of the NF-κB and STAT3 pathways. Through PKC and Wnt pathways, butyrate increases cancer cell differentiation. Furthermore, butyrate regulates oncogenic signaling molecules through microRNAs and methylation. Therefore, butyrate has the potential to be incorporated into cancer prevention and treatment regimens. In this review we summarize recent progress in butyrate research and discuss the future development of butyrate as an anti-cancer agent with emphasis on its effects on oncogenic signaling pathways. The low bioavailability of butyrate is a problem, which precludes clinical application. The disadvantage of butyrate for medicinal applications may be overcome by several approaches including nano-delivery, analogue development and combination use with other anti-cancer agents or phytochemicals. View Full-Text
Keywords: butyrate; short chain fatty acids; intestinal microbiota; cellular signaling butyrate; short chain fatty acids; intestinal microbiota; cellular signaling
Show Figures

Figure 1

MDPI and ACS Style

Chen, J.; Zhao, K.-N.; Vitetta, L. Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients 2019, 11, 1026.

AMA Style

Chen J, Zhao K-N, Vitetta L. Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients. 2019; 11(5):1026.

Chicago/Turabian Style

Chen, Jiezhong, Kong-Nan Zhao, and Luis Vitetta. 2019. "Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways" Nutrients 11, no. 5: 1026.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop